Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

C Sotiriou

Showing results (41-50 of 67) with videos related to

Pageof 7
Sort By:
European Journal of Nuclear Medicine and Molecular Imaging|April 5, 2018
Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancerDavid Groheux, L Biard, J Lehmann-Che, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2017
A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancerC Criscitiello, M A Bayar, G Curigliano, et al.
Cancer Treatment Reviews|December 24, 2014
Optimising translational oncology in clinical practice: strategies to accelerate progress in drug developmentR Stahel, J Bogaerts, F Ciardiello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 15, 2016
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumabS Loibl, I Majewski, V Guarneri, et al.
Breast Cancer Research and Treatment|December 1, 2010
Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAsA Smeets, A Daemen, I Vanden Bempt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 10, 2013
Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trialE de Azambuja, D Zardavas, M Lemort, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 4, 2014
Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancerF Rothé, J-F Laes, D Lambrechts, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 21, 2012
Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group StatementS Guiu, S Michiels, F André, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2019
Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)R Condorelli, F Mosele, B Verret, et al.
ESMO Open|May 4, 2024
The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumabL Buisseret, Y Bareche, D Venet, et al.
Pageof 7

Showing results (41-50 of 67) with videos related to

Sort By:
Pageof 7
European Journal of Nuclear Medicine and Molecular Imaging|April 5, 2018
Tumor metabolism assessed by FDG-PET/CT and tumor proliferation assessed by genomic grade index to predict response to neoadjuvant chemotherapy in triple negative breast cancerDavid Groheux, L Biard, J Lehmann-Che, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 28, 2017
A gene signature to predict high tumor-infiltrating lymphocytes after neoadjuvant chemotherapy and outcome in patients with triple-negative breast cancerC Criscitiello, M A Bayar, G Curigliano, et al.
Cancer Treatment Reviews|December 24, 2014
Optimising translational oncology in clinical practice: strategies to accelerate progress in drug developmentR Stahel, J Bogaerts, F Ciardiello, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|May 15, 2016
PIK3CA mutations are associated with reduced pathological complete response rates in primary HER2-positive breast cancer: pooled analysis of 967 patients from five prospective trials investigating lapatinib and trastuzumabS Loibl, I Majewski, V Guarneri, et al.
Breast Cancer Research and Treatment|December 1, 2010
Prediction of lymph node involvement in breast cancer from primary tumor tissue using gene expression profiling and miRNAsA Smeets, A Daemen, I Vanden Bempt, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 10, 2013
Phase I trial combining temozolomide plus lapatinib for the treatment of brain metastases in patients with HER2-positive metastatic breast cancer: the LAPTEM trialE de Azambuja, D Zardavas, M Lemort, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|September 4, 2014
Plasma circulating tumor DNA as an alternative to metastatic biopsies for mutational analysis in breast cancerF Rothé, J-F Laes, D Lambrechts, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 21, 2012
Molecular subclasses of breast cancer: how do we define them? The IMPAKT 2012 Working Group StatementS Guiu, S Michiels, F André, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|February 5, 2019
Genomic alterations in breast cancer: level of evidence for actionability according to ESMO Scale for Clinical Actionability of molecular Targets (ESCAT)R Condorelli, F Mosele, B Verret, et al.
ESMO Open|May 4, 2024
The long and winding road to biomarkers for immunotherapy: a retrospective analysis of samples from patients with triple-negative breast cancer treated with pembrolizumabL Buisseret, Y Bareche, D Venet, et al.
Pageof 7